Elizabeth Jungman, J.D., M.P.H.

Experience

THE PEW CHARITABLE TRUSTS Washington, DC
Director, Public Health Programs (November 2014-present)
Director, Drug Safety and Innovation (January 2014-October 2014)

- Direct public health projects including those focused on, respectively, antibiotics, drug safety, and health care products. Oversee policy experts, scientists, and advocates to ensure the effective execution of program goals including research and analysis, policy development, and advocacy.
    - Direct a major Pew initiative to address the growing threat of antibiotic resistance by promoting policies to improve stewardship in human health care and animal agriculture, and facilitate the development of new antibiotics.
    - Direct work to protect consumers from substandard, counterfeit, and adulterated medicines by supporting appropriate quality standards and oversight for drug manufacturing and drug compounding.
    - Launched a new initiative focused on ensuring safety of products overseen by the Food and Drug Administration (FDA) including over-the-counter drug products, laboratory-developed tests, dietary supplements, and drug promotion.
- Began a new project to utilize federal and state policy levers to reduce the serious health and economic consequences of prescription drug abuse; two years later launched expansion of that work to support evidence-based treatment options, including medication-assisted therapies.
- Represent Pew in public forums, external meetings, and legislative proceedings. Develop and maintain relationships with outside stakeholder organizations.
- Serve as on-the-record spokesperson; quoted in mainstream (*e.g. USA Today*, *Philadelphia Inquirer*, *St. Louis Post-Dispatch*), scientific (*Nature News, National Geographic*, *STAT*), trade (*e.g. Pink Sheet, Pharmacy Practice News*), and policy (*e.g. Politico*, *Bloomberg Law*, *CQ RollCall*, *Inside Health Policy*, *FDA News*) publications; interviewed on radio (*e.g. The Diane Rehm Show*, NPR's *Marketplace*, PBS's WTTW, NPR's KMUW, Iowa Public Radio) and television (*e.g. The Dr. Oz Show*).

U.S. SENATE COMMITTEE ON HEALTH, EDUCATION, LABOR & PENSIONS Washington, DC
Senior Health Policy Advisor (March 2011-December 2013)

- Lead staff member on FDA issues for the Senate Committee with authorizing jurisdiction over FDA.
- Played a key role in drafting and negotiating significant legislation on drug quality, drug safety, drug development, and related regulatory modernization:
    - The FDA Safety and Innovation Act of 2012, which included provisions related to pediatric research incentives, medical device approval, the safety of drug imports, expedited drug approvals, and other matters;
    - The FDA provisions in the Pandemic All-Hazards Preparedness Reauthorization Act of 2013, which included process changes to streamline the regulatory pathway for medical countermeasures; and
    - The Drug Quality and Security Act of 2013, which clarified the regulation of traditional compounders, created a new federal regulatory category for facilities that compound drugs outside of the traditional pharmacy setting, established a national tracking system to secure drug distribution, and raised licensure standards for pharmaceutical wholesale distributors.
- Advised Chairman Tom Harkin and Committee leadership and staff on legislative and oversight matters related to FDA.
- Engaged with stakeholder groups during policy development, including major national organizations in the consumer and public health advocacy communities. Worked with stakeholders to understand recommendations and refine policy proposals as appropriate to protect public health.

COVINGTON & BURLING LLP Washington, DC
Associate (October 2005-March 2011)

- Provided regulatory advice as a member of the firm's Food & Drug and Health Care practice groups.
- Developed deep technical expertise on a broad range of pharmaceutical law and regulatory topics. Advised clients on human pharmaceutical matters such as pharmaceutical advertising and promotion, Hatch-Waxman and pediatric exclusivity, bioequivalence, drug naming, and compliance programs.
- Counseled clients on health care issues including fraud and abuse risk analysis, price reporting, pharmaceutical and clinical trials reimbursement, drug coverage under the Medicare prescription drug program, and compliance with HIPAA and other medical privacy laws.
- Provided regulatory support for litigation pleadings and corporate transactions and filings.
- Pro-bono projects related to public benefits and end-of-life planning.

UNITED STATES COURT OF APPEALS, NINTH CIRCUIT Seattle, WA
Law Clerk for the Hon. Richard C. Tallman (August 2004–August 2005)

UNITED STATES DISTRICT COURT, CENTRAL DISTRICT OF CALIFORNIA Los Angeles, CA
Law Clerk for the Hon. Mariana R. Pfaelzer (August 2003–August 2004)

Professional Activities

PHARMACY COMPOUNDING ADVISORY COMMITTEE (PCAC)
Voting Member (November 2014-September 2016; September 2017-present)

The PCAC provides advice and recommendations to the Commissioner of the FDA on scientific, technical, and medical issues concerning drug compounding, including substances considered for FDA's lists of bulk substances that can be used in compounding, drugs that are demonstrably difficult to compound, and drugs withdrawn from the market for reasons of safety and effectiveness.

PRESIDENTIAL ADVISORY COMMITTEE ON COMBATTING ANTIBIOTIC RESISTANT BACTERIA (PACCARB)
Liaison Member (November 2014-September 2017)

The PACCARB provides advice, information, and recommendations to the Secretary of Health and Human Services regarding programs and policies intended to support and evaluate the implementation of U.S. government activities related to combating antibiotic-resistant bacteria.

FOOD AND DRUG LAW INSTITUTE (FDLI)
Board of Directors (January 2018-present)
Drugs and Biologics Committee (April 2015-January 2018)

FDLI is a nonprofit membership organization that offers education, training, publications, and professional engagement opportunities in the field of food and drug law. Active member of FDLI, speaker at conferences and webinars, and author of the forward for FDLI's primer on drug compounding.

DISTRICT OF COLUMBIA BAR
Member (2003-present)

Education

GEORGETOWN UNIVERSITY LAW CENTER: J.D., *cum laude*

JOHNS HOPKINS SCHOOL OF PUBLIC HEALTH: M.P.H., concentration in Health Policy & Management

HARVARD COLLEGE: A.B. in Biology, *cum laude*